drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Intravenous bispecific T-cell engager (BiTE) antibody construct that binds CD19 on B-lineage leukemia cells and CD3 on T cells, redirecting endogenous T cells to eliminate CD19+ blasts via immune-synapse formation and perforin/granzyme-mediated cytotoxicity.
nci_thesaurus_concept_id
C62528
nci_thesaurus_preferred_term
Blinatumomab
nci_thesaurus_definition
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.
drug_mesh_term
blinatumomab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
A bispecific single-chain antibody construct (BiTE) that binds CD19 on B-lineage cells and CD3 on T cells, bringing them together to form an immune synapse and activate T cells, leading to perforin/granzyme-mediated cytotoxic killing of CD19-positive leukemia cells.
drug_name
Blinatumomab
nct_id_drug_ref
NCT05837689